Biosimilar Zirabev Gets FDA Approval for 5 Types of Cancer
The FDA has approved Zirabev (bevacizumab-bvzr; Pfizer), a biosimilar to Avastin (bevacizumab; Genentech).
Cancer
Cancer Death Rates Decreased While Heart Disease Deaths Increased
Cancer death rates declined for adults aged 45 to 64 years from 1999 to 2017, while heart disease death rates decreased to 2011 and then increased.
AGA Clinical Practice Update: DAAs for Hepatitis C and Hepatocellular Cancer
The AGA present an updated summary of best practice advice for surveillance of hepatocellular cancer and DAA therapy timing.
Jury Finds Roundup a Major Contributor to Man’s Cancer
Edwin Hardeman alleged that exposure to the weedkiller Roundup led to his non-Hodgkin lymphoma.
HIV & Cancer Risk: Expert Interview
Although rates of AIDS-defining malignancies have declined in recent decades, cancer remains a leading cause of mortality in people living with HIV.
FDA: Lutathera Approved to Treat Gastroenteropancreatic Neuroendocrine Tumors
The radioactive drug is approved to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Transparent Estimates of Cancer Drug Research & Development: Are Patients Overspending?
The median cost of cancer drug development is $640 million, and revenue after approval is substantial.
Ovarian Cancer Survival Impacted by Hospital Quality, Volume
Both hospital volume and adherence to quality metrics are associated with survival rates for patients with ovarian cancer.
Increased Number of Patients Enrolled in Cancer Trials Under ACA
Under the Affordable Care Act, more privately insured patients have enrolled in clinical trials for cancer treatments.
FDA Reviewing Potential First US Gene Therapy
Tisagenlecleucel could be a one-time treatment for children and young adults with advanced leukemia.
